Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial

Ruperto, Nicolino; Brunner, Hermine; Synoverska, Olga; Ting, Tracy; Mendoza, Carlos; Spindler, Alberto; Vyzhga, Yulia; Marzan, Katherine; Grebenkina, Lyudmila; Tirosh, Irit; Imundo, Lisa; Jerath, Rita; Kingsbury, Daniel; Sozeri, Betul; Vora, Sheetal; Prahalad, Sampath; Zholobova, Elena; Aviel, Yonatan; Chasnyk, Vyacheslav; Lerman, Melissa; Nanda, Kabita; Schmeling, Heinrike; Tory, Heather; Uziel, Yosef; Viola, Diego; Posner, Holly; Kanik, Keith; Wouters, Ann; Chang, Cheng; Zhang, Richard; Lazariciu, Irina; Hsu, Ming-Ann; Suehiro, Ricardo; Martini, Alberto; Lovell, ÖZGÜR

doi:10.1016/s0140-6736(21)01255-1

Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial

Ruperto N., Brunner H., Synoverska O., Ting T., Mendoza C. A., Spindler A., ...Daha Fazla

LANCET, cilt.398, sa.10315, ss.1984-1996, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 398 Sayı: 10315
Basım Tarihi: 2021
Doi Numarası: 10.1016/s0140-6736(21)01255-1
Dergi Adı: LANCET
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Psycinfo, Veterinary Science Database
Sayfa Sayıları: ss.1984-1996
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background Tofacitinib is an oral Janus kinase inhibitor. This trial assessed the efficacy and safety of tofacitinib versus placebo in patients with polyarticular course juvenile idiopathic arthritis (JIA).